LLY

1,149.14

-0.93%↓

JNJ

236.12

+1.8%↑

ABBV

226.33

+1.84%↑

UNH

410.34

+1.2%↑

MRK

119.87

-0.03%↓

LLY

1,149.14

-0.93%↓

JNJ

236.12

+1.8%↑

ABBV

226.33

+1.84%↑

UNH

410.34

+1.2%↑

MRK

119.87

-0.03%↓

LLY

1,149.14

-0.93%↓

JNJ

236.12

+1.8%↑

ABBV

226.33

+1.84%↑

UNH

410.34

+1.2%↑

MRK

119.87

-0.03%↓

LLY

1,149.14

-0.93%↓

JNJ

236.12

+1.8%↑

ABBV

226.33

+1.84%↑

UNH

410.34

+1.2%↑

MRK

119.87

-0.03%↓

LLY

1,149.14

-0.93%↓

JNJ

236.12

+1.8%↑

ABBV

226.33

+1.84%↑

UNH

410.34

+1.2%↑

MRK

119.87

-0.03%↓

Home・Akcijų sąrašas・Design Therapeutics Inc

Design Therapeutics Inc

Atidarymo kaina

10.36 1.17

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

10.29

Max

10.76

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-1.6M -18M
Pelnas, tenkantis vienai akcijai	-0.29
Darbuotojai	54
EBITDA	-1.5M -20M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+84.04% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-148M 652M
Ankstesnė atidarymo kaina	9.19
Ankstesnė uždarymo kaina	10.36

Design Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-06-08 22:20; UTC

Įsigijimai, susijungimai, perėmimai

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

2026-06-08 15:41; UTC

Pagrindinės rinkos jėgos

American Battery Shares Jump on Energy Department Victory

2026-06-08 23:46; UTC

Rinkos pokalbiai

Nikkei May Rebound After Monday's Selloff -- Market Talk

2026-06-08 23:37; UTC

Rinkos pokalbiai

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

2026-06-08 23:25; UTC

Rinkos pokalbiai

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

2026-06-08 23:25; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-06-08 21:57; UTC

Įsigijimai, susijungimai, perėmimai

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

2026-06-08 21:56; UTC

Įsigijimai, susijungimai, perėmimai

Salesforce Agrees to Buy m3ter

2026-06-08 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-06-08 19:22; UTC

Rinkos pokalbiai

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

2026-06-08 19:01; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

2026-06-08 18:52; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2026-06-08 18:52; UTC

Rinkos pokalbiai

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

2026-06-08 18:17; UTC

Rinkos pokalbiai

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

2026-06-08 17:32; UTC

Rinkos pokalbiai

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

2026-06-08 17:29; UTC

Rinkos pokalbiai

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

2026-06-08 17:29; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-06-08 16:55; UTC

Įsigijimai, susijungimai, perėmimai

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

2026-06-08 16:54; UTC

Įsigijimai, susijungimai, perėmimai

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

2026-06-08 16:40; UTC

Rinkos pokalbiai

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

2026-06-08 16:31; UTC

Rinkos pokalbiai

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

2026-06-08 16:27; UTC

Rinkos pokalbiai

Mexican Inflation Seen Easing in May -- Market Talk

2026-06-08 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-06-08 16:03; UTC

Įsigijimai, susijungimai, perėmimai

Orange Bought Stake From Lorca

2026-06-08 16:01; UTC

Įsigijimai, susijungimai, perėmimai

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

2026-06-08 16:01; UTC

Įsigijimai, susijungimai, perėmimai

Orange Acquires 100% Ownership of MasOrange

2026-06-08 15:58; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-06-08 15:58; UTC

Rinkos pokalbiai

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

2026-06-08 15:55; UTC

Rinkos pokalbiai

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

2026-06-08 15:41; UTC

Rinkos pokalbiai

Gold Falls Below 200-Day Moving Average -- Market Talk

Akcijų palyginimas

Kainos pokytis

Design Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

84.04% į viršų

12 mėnesių prognozė

Vidutinis 19.6 USD 84.04%

Aukščiausias 22 USD

Žemiausias 15 USD

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Design Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

6 ratings

Pirkti

Laikyti

Parduoti

Remiantis 6 analitikų, pateikusių Design Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Design Therapeutics Inc

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.